Search for other papers by Marta Araujo-Castro in
Google Scholar
PubMed
Search for other papers by Betina Biagetti in
Google Scholar
PubMed
Search for other papers by Edelmiro Menéndez Torre in
Google Scholar
PubMed
Search for other papers by Iría Novoa-Testa in
Google Scholar
PubMed
Search for other papers by Fernando Cordido in
Google Scholar
PubMed
Search for other papers by Eider Pascual-Corrales in
Google Scholar
PubMed
Search for other papers by Víctor Rodríguez Berrocal in
Google Scholar
PubMed
Search for other papers by Fernando Guerrero-Pérez in
Google Scholar
PubMed
Search for other papers by Almudena Vicente in
Google Scholar
PubMed
Search for other papers by Juan Carlos Percovich Hualpa in
Google Scholar
PubMed
Search for other papers by Rogelio García-Centeno in
Google Scholar
PubMed
Search for other papers by Laura González-Fernández in
Google Scholar
PubMed
Search for other papers by María Dolores Ollero García in
Google Scholar
PubMed
Search for other papers by Ana Irigaray Echarri in
Google Scholar
PubMed
Search for other papers by María Dolores Moure Rodríguez in
Google Scholar
PubMed
Search for other papers by Cristina Novo-Rodríguez in
Google Scholar
PubMed
Search for other papers by María Calatayud in
Google Scholar
PubMed
Search for other papers by Rocío Villar-Taibo in
Google Scholar
PubMed
Search for other papers by Ignacio Bernabéu in
Google Scholar
PubMed
Search for other papers by Cristina Alvarez-Escola in
Google Scholar
PubMed
Search for other papers by Pamela Benítez Valderrama in
Google Scholar
PubMed
Search for other papers by Carmen Tenorio-Jiménez in
Google Scholar
PubMed
Department of Medicine and Surgery, Universidad Cardenal Herrera-CEU, CEU Universities, Castellón, Spain
Search for other papers by Pablo Abellán Galiana in
Google Scholar
PubMed
Search for other papers by Eva Venegas in
Google Scholar
PubMed
Search for other papers by Inmaculada González-Molero in
Google Scholar
PubMed
Search for other papers by Pedro Iglesias in
Google Scholar
PubMed
Search for other papers by Concepción Blanco-Carrera in
Google Scholar
PubMed
Search for other papers by Fernando Vidal-Ostos De Lara in
Google Scholar
PubMed
Search for other papers by Paz de Miguel Novoa in
Google Scholar
PubMed
Search for other papers by Elena López Mezquita in
Google Scholar
PubMed
Search for other papers by Felicia Alexandra Hanzu in
Google Scholar
PubMed
Neurological Tissue Bank of the Biobank, FCRB-IDIBAPS-Hospital Clinic Barcelona, Barcelona, Spain
Search for other papers by Iban Aldecoa in
Google Scholar
PubMed
Search for other papers by Silvia Aznar in
Google Scholar
PubMed
Search for other papers by Cristina Lamas in
Google Scholar
PubMed
Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain
Search for other papers by Anna Aulinas in
Google Scholar
PubMed
Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain
Search for other papers by Queralt Asla in
Google Scholar
PubMed
Search for other papers by Paola Gracia Gimeno in
Google Scholar
PubMed
Search for other papers by José María Recio-Córdova in
Google Scholar
PubMed
Search for other papers by María Dolores Avilés-Pérez in
Google Scholar
PubMed
Search for other papers by Diego Asensio-Wandosell in
Google Scholar
PubMed
Search for other papers by Miguel Sampedro-Núñez in
Google Scholar
PubMed
Search for other papers by Rosa Cámara in
Google Scholar
PubMed
Search for other papers by Miguel Paja Fano in
Google Scholar
PubMed
Search for other papers by Ignacio Ruz-Caracuel in
Google Scholar
PubMed
Search for other papers by Carmen Fajardo in
Google Scholar
PubMed
Search for other papers by Mónica Marazuela in
Google Scholar
PubMed
Search for other papers by Manel Puig-Domingo in
Google Scholar
PubMed
The objective of the study was to evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (GH) and prolactin (PRL) co-secreting pituitary neuroendocrine tumor (GH&PRL-Pit-NET) compared to their efficacy in patients with acromegaly caused by a GH-secreting pituitary neuroendocrine tumor (GH-Pit-NET). This is a multicenter retrospective study of patients with acromegaly on treatment with pasireotide and/or pegvisomant. Patients were classified in two groups: GH&PRL-Pit-NETs when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL were >200 ng/dL regardless of the PRL-IHC and GH-Pit-NETs when the previously mentioned criteria were not met. A total of 28 cases with GH&PRL-Pit-NETs and 122 with GH-Pit-NETs met the inclusion criteria. GH&PRL-Pit-NETs presented at a younger age, caused hypopituitarism, and were invasive more frequently than GH-Pit-NETs. There were 124 patients treated with pegvisomant and 49 with pasireotide at any time. The efficacy of pegvisomant for IGF-1 normalization was of 81.5% and of pasireotide of 71.4%. No differences in IGF-1 control with pasireotide and with pegvisomant were observed between GH&PRL-Pit-NETs and GH-Pit-NETs. All GH&PRL-Pit-NET cases treated with pasireotide (n = 6) and 82.6% (n = 19/23) of the cases treated with pegvisomant normalized PRL levels. No differences in the rate of IGF-1 control between pegvisomant and pasireotide were detected in patients with GH&PRL-Pit-NETs (84.9% vs 66.7%, P = 0.178). We conclude that despite the more aggressive behavior of GH&PRL-Pit-NETs than GH-Pit-NETs, no differences in the rate of IGF-1 control with pegvisomant and pasireotide were observed between both groups, and both drugs have shown to be effective treatments to control IGF-1 and PRL hypersecretion in these tumors.
Search for other papers by Cassia Michael in
Google Scholar
PubMed
Search for other papers by Juliana Moreira Mendonça-Gomes in
Google Scholar
PubMed
Search for other papers by Clinton Walton DePaolo in
Google Scholar
PubMed
Department of Medicine (Oncology), Albert Einstein College of Medicine, Bronx, New York, USA
Montefiore-Einstein Comprehensive Cancer Research Center, Albert Einstein College of Medicine, Bronx, New York, USA
Cancer Dormancy Tumor Microenvironment Institute, Albert Einstein College of Medicine, Bronx, New York, USA
Search for other papers by Antonio Di Cristofano in
Google Scholar
PubMed
Montefiore-Einstein Comprehensive Cancer Research Center, Albert Einstein College of Medicine, Bronx, New York, USA
Cancer Dormancy Tumor Microenvironment Institute, Albert Einstein College of Medicine, Bronx, New York, USA
Department of Medicine (Hepatology), Albert Einstein College of Medicine, Bronx, New York, USA
Marion Bessin Liver Research Center, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA
Search for other papers by Sofia de Oliveira in
Google Scholar
PubMed
Anaplastic thyroid cancer (ATC) is of the most aggressive thyroid cancer. While ATC is rare, it accounts for a disproportionately high number of thyroid cancer-related deaths. Here, we developed an ATC xenotransplant model in zebrafish larvae, where we can study tumorigenesis and therapeutic response in vivo. Using both mouse (T4888M) and human (C643)-derived fluorescently labeled ATC cell lines, we show these cell lines display different engraftment rates, mass volume, proliferation, cell death, angiogenic potential, and neutrophil and macrophage recruitment and infiltration. Next, using a PIP-FUCCI reporter to track proliferation in vivo, we observed cells in each phase of the cell cycle. Additionally, we performed long-term non-invasive intravital microscopy over 48 h to understand cellular dynamics in the tumor microenvironment at the single-cell level. Lastly, we tested two drug treatments, AZD2014 and a combination therapy of dabrafenib and trametinib, to show our model could be used as an effective screening platform for new therapeutic compounds for ATC. Altogether, we show that zebrafish xenotransplants make a great model to study thyroid carcinogenesis and the tumor microenvironment, while also being a suitable model to test new therapeutics in vivo.
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Search for other papers by Erin Gibbons in
Google Scholar
PubMed
Search for other papers by Manisha Taya in
Google Scholar
PubMed
Search for other papers by Huixing Wu in
Google Scholar
PubMed
Search for other papers by Samia H Lopa in
Google Scholar
PubMed
Search for other papers by Joel Moss in
Google Scholar
PubMed
Search for other papers by Elizabeth P Henske in
Google Scholar
PubMed
Search for other papers by Francis X McCormack in
Google Scholar
PubMed
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Search for other papers by Stephen R Hammes in
Google Scholar
PubMed
Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease affecting almost exclusively female-sexed individuals. The cysts represent regions of lung destruction caused by smooth muscle tumors containing mutations in one of the two tuberous sclerosis (TSC) genes. mTORC1 inhibition slows but does not stop LAM advancement. Furthermore, monitoring disease progression is hindered by insufficient biomarkers. Therefore, new treatment options and biomarkers are needed. LAM cells express melanocytic markers, including glycoprotein non-metastatic melanoma protein B (GPNMB). The function of GPNMB in LAM is currently unknown; however, GPNMB’s unique cell surface expression on tumor versus benign cells makes GPNMB a potential therapeutic target, and persistent release of its extracellular ectodomain suggests potential as a serum biomarker. Here, we establish that GPNMB expression is dependent on mTORC1 signaling, and that GPNMB regulates TSC2-null tumor cell invasion in vitro. Further, we demonstrate that GPNMB enhances TSC2-null xenograft tumor growth in vivo, and that ectodomain release is required for this xenograft growth. We also show that GPNMB’s ectodomain is released from the cell surface of TSC2-null cells by proteases ADAM10 and 17, and we identify the protease target sequence on GPNMB. Finally, we demonstrate that GPNMB’s ectodomain is present at higher levels in LAM patient serum compared to healthy controls and that ectodomain levels decrease with mTORC1 inhibition, making it a potential LAM biomarker.
Search for other papers by Bin Li in
Google Scholar
PubMed
Search for other papers by Sida Zhao in
Google Scholar
PubMed
Search for other papers by Yiyuan Chen in
Google Scholar
PubMed
Search for other papers by Hua Gao in
Google Scholar
PubMed
Search for other papers by Weiyan Xie in
Google Scholar
PubMed
Search for other papers by Hongyun Wang in
Google Scholar
PubMed
Search for other papers by Peng Zhao in
Google Scholar
PubMed
Search for other papers by Chuzhong Li in
Google Scholar
PubMed
Search for other papers by Yazhuo Zhang in
Google Scholar
PubMed
The clinical diagnosis and treatment of pituitary neuroendocrine tumors (PitNETs) that invade the cavernous sinus are fraught with difficulties and challenges. Exploring the biological characteristics involved in the occurrence and development of PitNETs that invade the cavernous sinus will help to elucidate the mechanism of cavernous sinus invasion. There are differences between intrasellar tumors (IST) and cavernous sinus-invasion tumors (CST) in ultramicrostructure, tumor microenvironment (TME), gene expression, and signaling pathways. The microvascular endothelial cell is increased in CST. The VEGFR signaling pathway, VEGF signaling pathway, and chemokine signaling pathway are activated in CST. HSPB1 is upregulated in CST and promotes cell proliferation, cell viability, and migration. HSPB1 promotes the release of VEGF from GT1-1 cells and activates the VEGF signaling pathway in bEnd.3 cells. HSPB1 promotes the migration of bEnd.3 cells to GT1-1 cells and promotes the formation of blood vessels of bEnd.3 cells. bEnd.3 cells can release CCL3 and CCL4 and promote the vitality, proliferation, and migration of GT1-1 cells. HSPB1 promotes the formation of blood vessels of bEnd.3 cells and ultimately leads to tumor growth in vivo. HSPB1 acts as a key gene for invasion of the cavernous sinus in PitNETs, remodeling TME by promoting the formation of blood vessels of brain microvascular endothelial cells. The synergistic effect of tumor cells and microvascular endothelial cells promotes tumor progression. The mechanism by which HSPB1 promotes tumor invasion by inducing angiogenesis in PitNETs may be a new target for the treatment of PitNETs invading the cavernous sinus.
Gastroenterology and Technologies for Health, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Lyon, France
Search for other papers by Laura Gerard in
Google Scholar
PubMed
Search for other papers by Céline Patte in
Google Scholar
PubMed
Search for other papers by Laurence Chardon in
Google Scholar
PubMed
Service Central d’Anatomie et Cytologie Pathologiques, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Search for other papers by Léa Payen in
Google Scholar
PubMed
Search for other papers by Marion Allio in
Google Scholar
PubMed
Search for other papers by Claire Marx in
Google Scholar
PubMed
Search for other papers by Hugo Clermidy in
Google Scholar
PubMed
Search for other papers by Alice Durand in
Google Scholar
PubMed
Search for other papers by Patrick Mehlen in
Google Scholar
PubMed
Search for other papers by Julien Bollard in
Google Scholar
PubMed
Search for other papers by Gilles Poncet in
Google Scholar
PubMed
Search for other papers by Colette Roche in
Google Scholar
PubMed
Search for other papers by Benjamin Gibert in
Google Scholar
PubMed
Gastroenterology and Technologies for Health, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Lyon, France
Search for other papers by Thomas Walter in
Google Scholar
PubMed
Neuropilin 2 (NRP2), a transmembrane non-tyrosine kinase receptor, has been described as a potential critical player in the tumourigenesis of several solid cancers and particularly in neuroendocrine neoplasms (NENs). A soluble form of NRP2 (sNRP2) has been previously described and corresponds to a truncated splice isoform. Its prognostic value has never been studied in NEN. NRP2 expression was studied by immunochemistry on tissue microarrays (n = 437) and on circulating tumour cells (CTCs, n = 5 patients with neuroendocrine carcinoma, NEC). We described the levels of sNRP2 in 229 patients with NEN using the ELISA method to identify the factors associated with sNRP2 levels and to evaluate its prognostic role; 90 blood donors represented the healthy control group. NRP2 was found in 97% of neuroendocrine tumours (396/410) and in 74% of NEC (20/27). NRP2 was also expressed in CTC of all the studied patients. The receiver operating characteristic (ROC) analysis showed that sNRP2 had a weak capacity to discriminate between NEN patients and healthy controls (area under curve (AUC) = 0.601, P = 0.053). Abnormal sNRP2 levels were associated with inflammatory syndrome, bone and peritoneal metastases, and abnormal chromogranin A levels. Patients with high sNRP2 levels (sNRP2Q3–Q4) had significantly poorer overall survival in multivariate analysis (HR 0.16, 95% CI (0.04–0.67), P = 0.015). In conclusion, the present study found that sNRP2 and NRP2 could represent a new prognostic biomarker and a therapeutic target, respectively, particularly in aggressive NEN.
Search for other papers by Katherine I Wolf in
Google Scholar
PubMed
Search for other papers by Linda Rose-Krasnor in
Google Scholar
PubMed
Search for other papers by Stephanie Alband in
Google Scholar
PubMed
Search for other papers by Jacques W M Lenders in
Google Scholar
PubMed
Search for other papers by Lauren Fishbein in
Google Scholar
PubMed
Pheochromocytoma and paragangliomas (PPGLs) originate from the chromaffin cells of the adrenal medulla or neural crest progenitors outside the adrenal gland, respectively. The estimated annual incidence of PPGL is between 2.0 and 8.0/million adults. Minimal data exist on the impact of PPGL from the patient’s perspective. Therefore, a survey was adapted from a previously published study on gastroenteropancreatic neuroendocrine tumors to explore the voice of patients with PPGL and learn ways to improve clinical care while understanding the current gaps to direct future research. A self-reported online survey was available to patients with PPGL and those with genetic predisposition even without PPGL from June to July 2022. Survey questions captured sociodemographic and clinical characteristics, the diagnostic workup, treatment and monitoring, quality and access to care, and financial impact. Here, we report the most relevant findings on patient experience of disease burden following diagnosis. A total of 270 people responded, the majority of whom were from the USA (79%), Caucasian (88%), and female (81%). The results of this survey highlight the burden of disease on a patient’s daily life, resulting in moderate to severe financial distress, increased travel time to specialized facilities resulting in loss of work and wages, and significant delays in care. Respondents reported being unheard and unacknowledged. With a median time to diagnosis just over 2 years, the physical, mental, and emotional toll are substantial. Increasing access to PPGL specialists and centers could lead to faster diagnoses and better management, which may reduce the burden on both patients and healthcare centers.
Search for other papers by Isabel Heidegger in
Google Scholar
PubMed
Search for other papers by Zoran Culig in
Google Scholar
PubMed
Search for other papers by Francesca Marini in
Google Scholar
PubMed
Search for other papers by Francesca Giusti in
Google Scholar
PubMed
Donatello Bone Clinic, Villa Donatello Hospital, Sesto Fiorentino, Italy
Search for other papers by Maria Luisa Brandi in
Google Scholar
PubMed
Insulinoma and glucagonoma are two rare functioning neoplasms of the neuroendocrine cells of the pancreas, respectively, characterized by an uncontrolled over-secretion of insulin or glucagon, responsible for the development of the hypoglycemic syndrome and the glucagonoma syndrome. They prevalently arise as sporadic tumors; only about 10% of cases develop in the context of rare inherited tumor syndromes, such as multiple endocrine neoplasia type 1 (MEN1), neurofibromatosis type 1 (NF1), and tuberous sclerosis complex (TSC), being the result of an autosomal-dominant germline heterozygous loss-of-function mutation in a tumor-suppressor gene. Here, we reviewed the main epidemiological and clinical aspects of insulinoma and glucagonoma in the context of genetic syndromes.
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Günter Klöppel in
Google Scholar
PubMed
Search for other papers by Lei Qiao in
Google Scholar
PubMed
Search for other papers by Chao Dong in
Google Scholar
PubMed
Search for other papers by Wenlei Jia in
Google Scholar
PubMed
Search for other papers by Gang Sun in
Google Scholar
PubMed
Breast cancer is the leading cause of cancer-related deaths in females, and triple-negative breast cancer (TNBC) is characterized as one of the main subtypes of breast cancer, with poor prognosis and limited treatments. Investigating the molecular basis or discovering relevant oncogenes will greatly help in developing effective targeted therapies. In this study, we ascertained that RAB5A depletion in TNBC cells suppresses the secretion of exosomes and blocks the polarization of macrophages toward an M2 phenotype. By scanning miRNAs associated with macrophage polarization, we identified that miR-21 was the pivotal component in tumor cell-derived exosomes and played a key role in RAB5A-mediated macrophage polarization. The enhanced expression of miR-21 in macrophages is able to potentiate the M2 polarization of macrophages in the presence of tumor cells. Pellino-1 (PELI1) was subsequently identified as the target of miR-21, and forced PELI1 expression partially abrogated the M2 polarization of macrophages induced by miR-21 overexpression. Macrophages stimulated with RAB5A-depleted TNBC cells (coculture, conditioned medium or exosomes) impaired their capability to promote the proliferation, migration, and invasion of tumor cells. In vivo xenograft experiments further confirmed that RAB5A knockdown TNBC cells exhibited reduced tumor formation and impaired tumor-associated macrophage recruitment. These studies shed light on the potential underlying mechanism of RAB5A-mediated macrophage polarization in an exosomal miR-21-dependent manner and provide an experimental basis for the development of RAB5A- or exosome-based tumor therapeutic strategies.
